Response Genetics' Q2 Revenues Drop 23 Percent as ResponseDX Sales Climb | GenomeWeb

NEW YORK (GenomeWeb) – Response Genetics today reported that its second quarter revenues declined 23 percent year over year, but were up 10 percent on a sequential basis.

The Los Angeles-based molecular diagnostics firm brought in total revenues of $4.3 million for the three months ended June 30, down from $5.3 million for the second quarter of 2013. The company said that the decline was due to pharmaceutical client revenue, which varies quarter to quarter. In addition, last year's Q2 included a $500,000 milestone payment from GlaxoSmithKline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.